Is Charles River Laboratories International (CRL) Fairly Valued After The Apollo Orchestrate Launch?
What the Apollo Orchestrate launch means for Charles River Laboratories International stock
Charles River Laboratories International (CRL) and Autolomous have launched Apollo Orchestrate, a digital workflow system for biologics quality control labs that links multiple platforms, automates execution, and moves records from paper to electronic formats.
The rollout starts in Good Manufacturing Practice settings across North America and Europe. It is creating a standardized, scalable operating framework that could matter for how investors think about efficiency, quality controls, and client visibility at the Biologics Testing Solutions unit.
Recent trading has been strong for Charles River Laboratories International, with a 1-day share price return of 1.27% and a 7-day move of 4.00%, building on a 30-day share price gain of 8.42% and a 90-day rise of 29.30% to reach US$301.79. That momentum sits alongside a 49.09% year-to-date share price return and a 1-year total shareholder return of 80.68%. However, the 5-year total shareholder return is down 25.21%, which keeps longer term expectations and risk perceptions in focus as investors weigh product launches like Apollo Orchestrate against the stock’s history.
Scan how Apollo-style digitization is playing out across the sector by reviewing hand-picked lab and life sciences specialists in the 34 healthcare AI stocks.
Charles River Laboratories International now looks like a stronger operator than it did five years ago, yet the share price has already sprinted ahead. Is this renewed execution already fully reflected in today’s US$301.79 valuation, or not?
Most Popular Narrative: 1% Undervalued
On the most widely followed view, Charles River Laboratories International trades just below an estimated fair value of $305.00, with that small gap hinging on whether execution matches an ambitious long range plan through 2030.
The analysts have a consensus price target of $305.0 for Charles River Laboratories International based on their expectations of its future earnings growth, profit margins and other risk factors.
Given the current share price of $295.01, the analyst price target of $305.0 is 3.3% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
See why 4 investors see Charles River Laboratories International as 1% undervalued.
Result: Fair Value of $305.00 (ABOUT RIGHT)
Still, the Charles River Laboratories International story can change quickly if demand softens in Discovery and Safety Assessment or if pricing pressure erodes already thin profitability.
Find out about the key risks to this Charles River Laboratories International narrative.
Another View: Charles River Laboratories International Through A Cash Flow Lens
The earlier discussion leaned on analyst targets and earnings assumptions. A second look using the SWS DCF model points to a future cash flow value of about $292.39, which sits below Charles River Laboratories International's recent price around $301.79 and frames the shares as slightly overvalued on this metric. That gap is not huge, but it does raise the question of which signal you treat as more important: the earnings narrative or the cash flow math.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Charles River Laboratories International for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 28 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on Charles River Laboratories International so far. If you want to move fast and build your own view of the trade off between opportunity and risk, start with the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Charles River Laboratories International?
If you stop with Charles River Laboratories International, you risk missing other opportunities that fit your style and time horizon just as well.
- Zero in on quality at a discount by scanning our curated pool of 28 high quality undervalued stocks that combine strong fundamentals with appealing pricing signals.
- Prioritize resilience and sleep better at night by reviewing a 31 resilient stocks with low risk scores that focuses on sturdier balance sheets and milder volatility profiles.
- Spot potential early movers before the crowd by working through a 20 high quality undiscovered gems that highlights fundamentally robust businesses still flying under most radars.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com